AZN - AstraZeneca's Tagrisso with chemo approved in China for lung cancer
2024-06-26 08:02:00 ET
More on AstraZeneca
- AstraZeneca's Oncology Success: Fueling Future Growth
- AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade)
- AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
- AstraZeneca lung cancer therapy Imfinzi fails in late-stage trial
- AstraZeneca adds novel systemic lupus erythematosus target with BenevolentAI